Levent Korkmaz

Levent Korkmaz

Auto-generated profile, based on publicly available information

Levent Korkmaz

Department of Medical Oncology, Necmettin Erbakan University Meram Medical Faculty, Konya, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2016 in Current Eye Research
Verified
Journal Article
Closed access
PDF file
LKLevent Korkmaz
Levent Korkmaz
OBOsman Baştuğ
Osman Baştuğ
AOAhmet Ozdemir
Ahmet Ozdemir
SKSabriye Korkut
Sabriye Korkut
CKCagatay Karaca
Cagatay Karaca
MOMehmet Ozturk
Mehmet Ozturk
Purpose: Retinopathy of Prematurity (ROP) is a proliferative vitreoretinopathy which is one of the most frequent causes of blindness in children. In an attempt to find a solution to this important problem in preterm children, the search for new, effective treatment modalities with fewer side effects is underway. In our study, which was planned for this reason, we aimed to investigate the effects of propranolol treatment applied to cases of ROP in various stages during the second phase (known as the neovascularization-hypoxia phase) and to determine the correlation of these effects with the platelet mass index (PMI). Method: A total of 171 preterm infants at risk of ROP were selected randomly for inclusion in the study. All of the patients were classified according to their stage of ROP and were divided into control and treatment groups. While the cases in the control group were administered physiological saline solution, those in the treatment group were administered propranolol in the period that corresponded to the second stage of the disease. The thrombocyte and PMI values in the first and second stages of each study group were recorded. Results: A significant difference was found between the control and treatment groups of the stage 2 ROP study subjects. In the stage 2 ROP study group, no significant difference was detected between the control and treatment cases in terms of platelet counts in phase 1 or in the PMI values and the thrombolytic counts in phase 2. On the other hand, in phase 2 of the stage 2 ROP study subjects significant differences were detected between the control and treatment group in terms of PMI values. Conclusion: In the study, it was found in the stage 2 ROP study group that propranolol reduced the need for laser photocoagulation significantly. Also, in parallel to the efficacy of propranolol in this study group, a decrease was observed in PMI values.

1 August 2016 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MAMehmet Artac
Mehmet Artac
HÇHasan Şenol Çoşkun
Hasan Şenol Çoşkun
LKLevent Korkmaz
Levent Korkmaz
MKMurat Koçer
Murat Koçer
NTNazım Serdar Turhal
Nazım Serdar Turhal
ADAhmet Demirkazık
Ahmet Demirkazık

15 September 2026 in Pattern Recognition Letters
Verified
Journal Article
Open access
Omer AydinOmer Aydin
Omer Aydin
LKLevent Korkmaz
Levent Korkmaz
Aybeyan SelimAybeyan Selim
Aybeyan Selim
MKMurat Kuzlu
Murat Kuzlu
Ferhat Ozgur CatakFerhat Ozgur Catak
Ferhat Ozgur Catak
Umit CaliUmit Cali
Umit Cali